PMID- 30045288
OWN - NLM
STAT- MEDLINE
DCOM- 20180802
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 30
DP  - 2018 Jul
TI  - Increased intracranial pressure in Guillain-Barre syndrome: A case report.
PG  - e11584
LID - 10.1097/MD.0000000000011584 [doi]
LID - e11584
AB  - RATIONALE: Guillain-Barre syndrome (GBS) is an inflammatory autoimmune 
      demyelinating polyneuropathy that affects most of the peripheral nervous system. 
      Papilledema and raised intracranial pressure (ICP) are seen in some patients, and 
      are thought to be associated with elevated cerebrospinal fluid (CSF) 
      protein-though CSF protein levels are normal in some patients, thus the specific 
      mechanisms remain unclear. Interleukin (IL)-17 levels are elevated in the CSF and 
      plasma in GBS patients, and elevated IL-17 in the CSF of patients with idiopathic 
      intracranial hypertension has been reported. Intravenous immunoglobulin (IVIG) 
      exerts therapeutic effects by downregulating IL-17 in GBS patients. PATIENT 
      CONCERNS: Herein we describe a case of a 14-year-old girl who initially presented 
      with relapsing limb weakness. DIAGNOSES: Magnetic resonance imaging revealed an 
      enlarged ventricle, electromyography, and nerve conduction studies were 
      suggestive of polyradiculopathy, and lumbar puncture revealed elevated ICP with 
      normal cells and elevated protein values. INTERVENTIONS: She was treated with 
      IVIG 0.4 g/kg per day for 5 days. OUTCOMES: At a 6-month follow-up there had been 
      no recurrence. LESSONS SUBSECTIONS: In GBS patients who have a relapsing course 
      and develop papilledema with possible immunological disturbance, an accurate 
      early diagnosis in conjunction with the prompt initiation of immunotherapy may 
      improve clinical symptoms and the prognosis.
FAU - Zhao, Pan-Pan
AU  - Zhao PP
AD  - Department of Neurology, First Affiliated Hospital of Xinxiang Medical University 
      Henan Key Laboratory of Neural Regeneration Department of Neurosurgery, First 
      Affiliated Hospital of Xinxiang Medical University, Weihui, China.
FAU - Ji, Qian-Kun
AU  - Ji QK
FAU - Sui, Rui-Bin
AU  - Sui RB
FAU - Zhang, Rong
AU  - Zhang R
FAU - Zhang, Li-Jun
AU  - Zhang LJ
FAU - Xu, Zhi-Xiu
AU  - Xu ZX
FAU - Li, Qing
AU  - Li Q
FAU - Ji, Si-Bei
AU  - Ji SB
FAU - Zhao, Jian-Hua
AU  - Zhao JH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (IL17A protein, human)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-17)
SB  - IM
MH  - Adolescent
MH  - Female
MH  - Guillain-Barre Syndrome/*complications/drug therapy/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Interleukin-17/blood
MH  - Intracranial Hypertension/drug therapy/*immunology
MH  - Muscle Weakness/drug therapy/*immunology
PMC - PMC6078745
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/07/26 06:00
MHDA- 2018/08/03 06:00
PMCR- 2018/07/27
CRDT- 2018/07/26 06:00
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2018/08/03 06:00 [medline]
PHST- 2018/07/27 00:00 [pmc-release]
AID - 00005792-201807270-00041 [pii]
AID - MD-D-18-02167 [pii]
AID - 10.1097/MD.0000000000011584 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(30):e11584. doi: 10.1097/MD.0000000000011584.